Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) has announced it will host a live conference call and audio webcast on August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and provide a business overview. The company is developing DNAbilize®, a novel RNAi nanoparticle drug technology administered via intravenous transfusion.

Bio-Path's pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. An IND is expected for BP1003, a STAT3 inhibitor.

Positive

• DNAbilize® technology yielding a pipeline of RNAi nanoparticle drugs
• Multiple drug candidates in various clinical trial phases
• Diverse portfolio targeting both blood cancers and solid tumors

Negative

• None.

HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and to provide a business overview.

To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:                   

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings (BPTH) report its Q2 2024 financial results?

Bio-Path Holdings (BPTH) will report its Q2 2024 financial results on August 15, 2024, during a live conference call and audio webcast at 8:30 a.m. ET.

What is the current status of Bio-Path Holdings' (BPTH) lead product candidate?

Bio-Path Holdings' lead product candidate, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers.

How many drug candidates does Bio-Path Holdings (BPTH) have in its pipeline?

Bio-Path Holdings (BPTH) has at least four drug candidates in its pipeline: prexigebersen (BP1001), BP1001-A, BP1002, and BP1003 (pending IND filing).

What is the delivery method for Bio-Path Holdings' (BPTH) DNAbilize® technology?

Bio-Path Holdings' DNAbilize® technology yields RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion.